Literature DB >> 23797811

Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia.

Francesco Liistro1, Italo Porto, Paolo Angioli, Simone Grotti, Lucia Ricci, Kenneth Ducci, Giovanni Falsini, Giorgio Ventoruzzo, Filippo Turini, Guido Bellandi, Leonardo Bolognese.   

Abstract

BACKGROUND: The 1-year restenosis rate after balloon angioplasty of long lesions in below-the-knee arteries may be as high as 70%. Our aim was to investigate the efficacy of a paclitaxel drug-eluting balloons versus conventional percutaneous transluminal angioplasty (PTA) for the reduction of restenosis in diabetic patients with critical limb ischemia undergoing endovascular intervention of below-the-knee arteries. METHODS AND
RESULTS: The Drug-Eluting Balloon in Peripheral Intervention for below the knee angioplasty evaluation (DEBATE-BTK) is a randomized, open-label, single-center study comparing drug-eluting balloons and PTA. Inclusion criteria were diabetes mellitus, critical limb ischemia (Rutherford class 4 or higher), significant stenosis or occlusion >40 mm of at least 1 below-the-knee vessel with distal runoff, and life expectancy >1 year. Binary in-segment restenosis at a 1-year angiographic or ultrasonographic follow-up was the primary end point. Clinically driven target lesion revascularization, major amputation, and target vessel occlusion were the secondary end points. One hundred thirty-two patients with 158 infrapopliteal atherosclerotic lesions were enrolled. Mean length of the treated segments was 129±83 mm in the drug-eluting balloon group compared with 131±79 mm in the PTA group (P=0.7). Binary restenosis, assessed by angiography in >90% of patients, occurred in 20 of 74 lesions (27%) in the drug-eluting balloon group compared with 55 of 74 lesions (74%) in the PTA group (P<0.001); target lesion revascularization, in 12 (18%) versus 29 (43%; P=0.002); and target vessel occlusion, in 12 (17%) versus 41 (55%; P<0.001). Only 1 major amputation occurred, in the PTA group (P=0.9).
CONCLUSIONS: Drug-eluting balloons compared with PTA strikingly reduce 1-year restenosis, target lesion revascularization, and target vessel occlusion in the treatment of below-the-knee lesions in diabetic patients with critical limb ischemia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23797811     DOI: 10.1161/CIRCULATIONAHA.113.001811

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  47 in total

1.  Outcomes of infrapopliteal angioplasty for limb salvage based on the updated TASC II classification.

Authors:  Hong Kuan Kok; Hamed Asadi; Mark Sheehan; Frank P McGrath; Mark F Given; Michael J Lee
Journal:  Diagn Interv Radiol       Date:  2017 Sep-Oct       Impact factor: 2.630

2.  An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II): The TASC Steering Comittee(.).

Authors:  Michael R Jaff; Christopher J White; William R Hiatt; Gerry R Fowkes; John Dormandy; Mahmood Razavi; Jim Reekers; Lars Norgren
Journal:  Ann Vasc Dis       Date:  2015-10-23

3.  Diabetes: Drug-eluting balloons for the treatment of critical limb ischaemia.

Authors:  Megan Cully
Journal:  Nat Rev Cardiol       Date:  2013-07-09       Impact factor: 32.419

Review 4.  Endovascular intervention for peripheral artery disease.

Authors:  Arun K Thukkani; Scott Kinlay
Journal:  Circ Res       Date:  2015-04-24       Impact factor: 17.367

Review 5.  Endovascular Treatment of Infrapopliteal Peripheral Artery Disease.

Authors:  Ehrin J Armstrong; Kalkidan Bishu; Stephen W Waldo
Journal:  Curr Cardiol Rep       Date:  2016-04       Impact factor: 2.931

Review 6.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh
Journal:  Circulation       Date:  2016-11-13       Impact factor: 29.690

Review 7.  The Contemporary Role of Stents and Angioplasty for the Treatment of Infrapopliteal Disease in Critical Limb Ischemia.

Authors:  Tarek A Hammad; Anand Prasad
Journal:  Curr Cardiol Rep       Date:  2017-07       Impact factor: 2.931

8.  "Ranger BTK" a Prospective Single-Centre Cohort Study on a New Drug-Coated Balloon for Below the Knee Lesions in Patients with Critical Limb Ischemia.

Authors:  Costantino Del Giudice; Alexandre Galloula; Clarisse Tiercelin; Aurélie Vilfaillot; Jean Marc Alsac; Emmanuel Messas; Carole L Déan; Etienne Larger; Marc Sapoval
Journal:  Cardiovasc Intervent Radiol       Date:  2021-05-04       Impact factor: 2.740

9.  Endovascular Devices and Revascularization Techniques for Limb-Threatening Ischemia in Individuals With Diabetes.

Authors:  Jayer Chung
Journal:  J Diabetes Sci Technol       Date:  2017-03-28

10.  Network meta-analysis of balloon angioplasty, nondrug metal stent, drug-eluting balloon, and drug-eluting stent for treatment of infrapopliteal artery occlusive disease.

Authors:  Yaowen Xiao; Zhong Chen; Yaoguo Yang; Lei Kou
Journal:  Diagn Interv Radiol       Date:  2016 Sep-Oct       Impact factor: 2.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.